Clinical Research Directory

Inclusion Criteria: * Pathologically proven solid tumor malignancy (except for small cell lung cancer \[SCLC\], germ cell tumor) * Karnofsky performance status \>= 60 * 1 to 10 brain metastases (mets) (no more than two lesions and/or cavities \>= 3 cm in maximum diameter) * Maximum diameter of brain metastasis or resection cavity is 6 cm * Serum creatinine =\< 3 mg/dL and creatinine clearance \>= 30 ml/min * Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol * Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose * Patient able to provide his/her own written informed consent and speak English Exclusion Criteria: * Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor * Prior brain surgery =\< 14 days prior to enrollment * Planned chemotherapy during radiosurgery * Leptomeningeal metastases * Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months * Pregnant women